Dabigatran Etexilate Versus Warfarin in the Treatment of Venous Thromboembolism

被引：0
|
作者：
Schulman, Sam [1 ]
Eriksson, Henry [2 ]
Goldhaber, Samuel Z. [3 ]
Kakkar, Ajay K. [4 ]
Kearon, Clive [5 ]
Mismetti, Patrick [6 ]
Schellong, Sebastian M. [7 ]
Baanstra, David [8 ]
Schnee, Janet [9 ]
机构：
[1] McMaster Univ, Dept Med, Hamilton, ON, Canada
[2] Sahlgrens Univ Hosp, Gothenburg, Sweden
[3] Brigham & Womens Hosp, Boston, MA 02115 USA
[4] Barts & London Queen Marys Sch Med & Dent, Thrombosis Res Inst, London, England
[5] McMaster Univ Clin, Henderson Hosp, Hamilton, ON, Canada
[6] Bellevue Hosp, St Etienne, France
[7] Municipal Hosp Friedrichstadt, Med Div 2, Dresden, Germany
[8] Boehringer Ingelheim GmbH & Co KG, Clin Res, Alkmaar, Netherlands
[9] Boehringer Ingelheim GmbH & Co KG, Ridgefield, CT USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3 / 3
页数：1
相关论文
共 50 条
  • [41] APIXABAN AND RIVAROXABAN VERSUS WARFARIN FOR TREATMENT OF VENOUS THROMBOEMBOLISM IN OBESE PATIENTS
    Kafka, Wesley
    Cook, Stephen
    Ferris, Jessica
    Hill, Sharon
    CRITICAL CARE MEDICINE, 2020, 48
  • [42] SAFETY AND EFFECTIVENESS OF APIXABAN VERSUS WARFARIN IN THE TREATMENT AND PREVENTION OF VENOUS THROMBOEMBOLISM
    Weycker, Derek
    Li, Xiaoyan
    Wygant, Gail
    Lee, Theodore
    Hamilton, Melissa
    Luo, Xuemei
    Vo, Lien
    Mardekian, Jack
    Pan, Xianying
    Burns, Leah
    Atwood, Mark
    Cohen, Alexander
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 1953 - 1953
  • [43] New therapeutic option for thromboembolism - dabigatran etexilate
    Nishio, Hiroshi
    Ieko, Masahiro
    Nakabayashi, Toru
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (14) : 2509 - 2517
  • [44] Dabigatran etexilate and LMWH for the prevention of venous thromboembolism in 532 patients undergoing hip surgery
    Bonarelli, S.
    Bacchin, M. R.
    Frugiuele, I.
    Feoli, M. A.
    Facchini, F.
    Altimari, V.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2015, 19 (05) : 897 - 903
  • [45] Edoxaban versus Warfarin for Venous Thromboembolism Reply
    Bueller, Harry R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (01): : 80 - 81
  • [46] Dabigatran For The Treatment And Secondary Prevention Of Venous Thromboembolism
    Stevanovic, J.
    Kappelhoff, B.
    Voorhaar, M.
    Postma, M. J.
    VALUE IN HEALTH, 2015, 18 (07) : A393 - A393
  • [47] Influence of cancer on the efficacy and safety of dabigatran vs. warfarin for the acute and extended treatment of venous thromboembolism
    Schulman, S.
    Eriksson, H.
    Goldhaber, S. Z.
    Kakkar, A.
    Kearon, C.
    Schellong, S.
    Feuring, M.
    Friedman, J.
    Kreuzer, J.
    THROMBOSIS RESEARCH, 2014, 133 : S221 - S221
  • [48] Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting
    Jugrin, Anamaria Vera
    Hoesel, Volker
    Ustyugova, Anastasia
    De Francesco, Maria
    Lamotte, Mark
    Sunderland, Tom
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (01) : 1 - 10
  • [49] Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism
    Halton, Jacqueline M. L.
    Picard, Anne-Caroline
    Harper, Ruth
    Huang, Fenglei
    Brueckmann, Martina
    Gropper, Savion
    Maas, Hugo
    Tartakovsky, Igor
    Nurmeev, Ildar
    Mitchell, Lesley G.
    Brandao, Leonardo R.
    Chalmers, Elizabeth
    Albisettil, Manuela
    THROMBOSIS AND HAEMOSTASIS, 2017, 117 (11) : 2168 - 2175
  • [50] Dabigatran etexilate/rivaroxabanIntracranial haemorrhage, ischaemic stroke and recurrent venous thromboembolism: 3 case reports
    Reactions Weekly, 2015, 1542 (1) : 89 - 89
12345